Primary Viral Defensive Care in the New Year

The medical story and advice comes from Swiss Policy Research article On the Treatment of Covid-19.  This is what primary care physicians are recommending in many parts of the world, and what should be the generally accepted practice everywhere.  Excerpts in italics with my bolds.

Based on the available scientific evidence and current clinical experience, the SPR Collaboration recommends that physicians and authorities consider the following covid-19 treatment protocol for the prophylactic and early treatment of people at high risk or high exposure.

Numerous international studies have shown that prophylactic and early treatment can significantly reduce the risk of severe or fatal covid-19 (see scientific references in linked article).

Note: Patients are asked to consult a doctor.

Treatment protocol


Zinc (25mg to 50mg per day)
Quercetin (250mg to 500mg per day)
Bromhexine (24mg to 36mg per day)*
Vitamin D (2000 IU per day)
Vitamin C (1000mg per day)

Early treatment

Zinc (75mg to 150mg per day)
Quercetin (500mg to 1000mg per day)
Vitamins D (5000 u/d) and C (1000mg/d)
Bromhexine (50mg to 100mg per day)*
Aspirin (162mg to 325mg per day)*

Prescription only

Ivermectin (12mg per day for 2 days)*
High-dose vitamin D (up to 100,000 IU)
Azithromycin (up to 500mg per day)
Prednisone (60mg to 80mg per day)*
Hydroxychloroquine (400mg per day)*

(*) Notes:

Contraindications for aspirin and bromhexine must be observed. Ivermectin may also be used prophylactically on a weekly basis. Prednisone is to be used if pulmonary symptoms develop. Correctly dosed HCQ has been shown to be effective and safe for the early treatment of covid-19.

Modes of action
  • Zinc inhibits RNA polymerase activity of coronaviruses and thus blocks virus replication, as first discovered by world-leading SARS virologist Ralph Baric in 2010.
  • Ivermectin (an antiparasitic drug) has strong anti-viral and anti-inflammatory properties.
  • Quercetin (a plant polyphenol) supports the cellular absorption of zinc and has additional anti-viral properties, as first discovered during the SARS-1 epidemic in 2003.
  • Bromhexine (a mucolytic cough medication) inhibits the expression of cellular TMPRSS2 protease and thus the entry of the virus into the cell, as first described in 2017.
  • Vitamins C and D support and improve the immune system response to infections.
  • Aspirin may help prevent infection-related thrombosis and embolisms in patients at risk.
  • Azithromycin (an antibiotic) prevents bacterial superinfections of the lung.
  • Prednisone (a corticosteroid) reduces covid-related systemic inflammation.
  • HCQ has known anti-viral, anti-thrombotic and anti-inflammatory properties.

The early treatment of patients as soon as the first typical symptoms appear and even without a PCR test is essential to prevent progression of the disease. In contrast, isolating infected high-risk patients at home and without early treatment until they develop serious respiratory problems, as often happened during lockdowns, may be counterproductive.

People at high risk living in an epidemically active area should consider prophylactic treatment together with their doctor. The reason for this is the long incubation period of covid-19 (up to 14 days): when patients first notice that they contracted the disease, the viral load is already at a maximum and there are often only a few days left to react with an early treatment intervention.

Early treatment based on the above protocol is intended to avoid hospitalization. If hospitalization nevertheless becomes necessary, experienced ICU doctors recommend avoiding invasive ventilation (intubation) whenever possible and using oxygen therapy (HFNC) instead.

It is conceivable that the above treatment protocol, which is simple, safe and inexpensive, could render more complex medications, vaccinations, and other measures largely obsolete.

Footnote: New Ivermectin Results

WHO-commissioned review of ivermectin trials finds 83% reduction in covid mortality.

Dr Andrew Hill of the Department of Pharmacology at the University of Liverpool (UK) is currently performing a WHO-commissioned review and meta-analysis of randomized controlled trials of ivermectin against covid. In the following 12-minute video, Dr Hill is presenting his preliminary results, which confirm a highly significant 83% reduction in covid mortality (95% CI 65%-92%).

This result is based on in-hospital trials, so it doesn’t even take into account early ambulatory and prophylactic treatment. The WHO now wants to wait for three more trials, due to be published sometime in January, before issuing an official recommendation. At the end of his presentation, Dr Hill speaks of ivermectin as a potentially “transformational treatment”.

via Science Matters

January 2, 2021 at 08:26AM

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s